EFFICACY AND RISKS PROFILES OF “GLP-1 RECEPTOR AGONISTS” IN TYPE 2 DIABETES AND OBESITY: A SYSTEMATIC REVIEW OF BENEFITS AND RISKS. rjnmsr 2025, 3 (5), 300-324. https://doi.org/10.63075/fmkjkn28.